Loading...
Loading...
AMLX| Name | Value |
|---|---|
| Revenues | 21.9M |
| Cost of Revenue | 2.8M |
| Gross Profit | 19.1M |
| Operating Expense | 63.7M |
| Operating I/L | -44.6M |
| Other Income/Expense | 2.5M |
| Interest Income | 3.2M |
| Pretax | -42.1M |
| Income Tax Expense | 0.6M |
| Net Income/Loss | -42.7M |
Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Their primary product in the pipeline is AMX0035, a dual UPR-Bax apoptosis inhibitor designed for the treatment of ALS. The company also aims to expand the application of AMX0035 to other neurodegenerative diseases, positioning itself as a leader in addressing these challenging medical conditions.
